305 related articles for article (PubMed ID: 37338709)
1. Perspectives on Mycophenolate Mofetil in the Management of Autoimmunity.
Bhat R; Tonutti A; Timilsina S; Selmi C; Gershwin ME
Clin Rev Allergy Immunol; 2023 Aug; 65(1):86-100. PubMed ID: 37338709
[TBL] [Abstract][Full Text] [Related]
2. Mycophenolate mofetil limits renal damage and prolongs life in murine lupus autoimmune disease.
Corna D; Morigi M; Facchinetti D; Bertani T; Zoja C; Remuzzi G
Kidney Int; 1997 May; 51(5):1583-9. PubMed ID: 9150476
[TBL] [Abstract][Full Text] [Related]
3. An update on the use of mycophenolate mofetil in lupus nephritis and other primary glomerular diseases.
Appel AS; Appel GB
Nat Clin Pract Nephrol; 2009 Mar; 5(3):132-42. PubMed ID: 19174771
[TBL] [Abstract][Full Text] [Related]
4. Mycophenolate mofetil therapy for children with lupus nephritis refractory to both intravenous cyclosphosphamide and cyclosporine.
Fu YF; Liu GL
Clin Nephrol; 2001 Apr; 55(4):318-21. PubMed ID: 11334319
[TBL] [Abstract][Full Text] [Related]
5. Mycophenolate mofetil in low doses stabilizes and improves antineutrophil cytoplasmic antibody-associated vasculitis and lupus nephritis.
Kazderova M; Jancova E; Rysava R; Merta M; Tesar V
Arch Med Res; 2008 Jan; 39(1):115-9. PubMed ID: 18068004
[TBL] [Abstract][Full Text] [Related]
6. Immunosuppressive treatment for proliferative lupus nephritis.
Tunnicliffe DJ; Palmer SC; Henderson L; Masson P; Craig JC; Tong A; Singh-Grewal D; Flanc RS; Roberts MA; Webster AC; Strippoli GF
Cochrane Database Syst Rev; 2018 Jun; 6(6):CD002922. PubMed ID: 29957821
[TBL] [Abstract][Full Text] [Related]
7. Real-World Experience of Safety of Mycophenolate Mofetil in 119 Japanese Patients with Systemic Lupus Erythematosus: A Retrospective Single-Center Study.
Abe Y; Tada K; Yamaji K; Tamura N
Biomed Res Int; 2021; 2021():8630596. PubMed ID: 33564682
[TBL] [Abstract][Full Text] [Related]
8. Lupus nephritis: treatment with mycophenolate mofetil.
Kapitsinou PP; Boletis JN; Skopouli FN; Boki KA; Moutsopoulos HM
Rheumatology (Oxford); 2004 Mar; 43(3):377-80. PubMed ID: 14963204
[TBL] [Abstract][Full Text] [Related]
9. Mycophenolate mofetil therapy in lupus nephritis: clinical observations.
Dooley MA; Cosio FG; Nachman PH; Falkenhain ME; Hogan SL; Falk RJ; Hebert LA
J Am Soc Nephrol; 1999 Apr; 10(4):833-9. PubMed ID: 10203368
[TBL] [Abstract][Full Text] [Related]
10. Neuropsychiatric Systemic Lupus Erythematosus with Cerebral Vasculitis and Lupus Nephritis Successfully Treated with High-dose Glucocorticoids and Mycophenolate Mofetil.
Tanaka S; Kawaguchi T; Kudo R; Kimura M; Rikitake Y; Iwao C; Rikitake M; Iwao K; Aizawa A; Kariya Y; Matsuda M; Miyauchi S; Takajo I; Umekita K
Intern Med; 2022 Oct; 61(20):3131-3135. PubMed ID: 35283391
[TBL] [Abstract][Full Text] [Related]
11. Treatment of Class IV Lupus Nephritis with Mycophenolate Mofetil Monotherapy.
Nawata T; Kubo M; Fujii S; Shiragami K; Ikegami T; Kobayashi S; Hisano S; Yano M
Intern Med; 2018 Jul; 57(14):2067-2070. PubMed ID: 29491296
[TBL] [Abstract][Full Text] [Related]
12. The efficacy of low-dose mycophenolate mofetil for treatment of lupus nephritis in Taiwanese patients with systemic lupus erythematosus.
Weng MY; Weng CT; Liu MF
Clin Rheumatol; 2010 Jul; 29(7):771-5. PubMed ID: 20195879
[TBL] [Abstract][Full Text] [Related]
13. Use of mycophenolate mofetil for systemic sclerosis and systemic sclerosis-associated interstitial lung disease: Information from a Japanese hospital claims database.
Funatogawa T; Narita Y; Tamura A; Mii K; Sugitani Y; Uchida T
Mod Rheumatol; 2022 Jul; 32(4):755-760. PubMed ID: 34850080
[TBL] [Abstract][Full Text] [Related]
14. Mycophenolate mofetil in lupus nephritis.
Ginzler EM; Aranow C
Lupus; 2005; 14(1):59-64. PubMed ID: 15732290
[TBL] [Abstract][Full Text] [Related]
15. Efficacy of mycophenolate mofetil versus cyclophosphamide in systemic sclerosis-related interstitial lung disease: a systematic review and meta-analysis.
Ma X; Tang R; Luo M; Zeng Z; Shi Y; Tang B; Xiao R
Clin Rheumatol; 2021 Aug; 40(8):3185-3193. PubMed ID: 34080081
[TBL] [Abstract][Full Text] [Related]
16. Use of mycophenolate mofetil in autoimmune and renal diseases.
Appel GB; Radhakrishnan J; Ginzler EM
Transplantation; 2005 Oct; 80(2 Suppl):S265-71. PubMed ID: 16251859
[TBL] [Abstract][Full Text] [Related]
17. Cyclophosphamide versus mycophenolate mofetil in scleroderma interstitial lung disease (SSc-ILD) as induction therapy: a single-centre, retrospective analysis.
Shenoy PD; Bavaliya M; Sashidharan S; Nalianda K; Sreenath S
Arthritis Res Ther; 2016 Jun; 18(1):123. PubMed ID: 27255492
[TBL] [Abstract][Full Text] [Related]
18. Mycophenolate mofetil is an effective and safe option for the management of systemic sclerosis-associated interstitial lung disease: results from the Australian Scleroderma Cohort Study.
Owen C; Ngian GS; Elford K; Moore O; Stevens W; Nikpour M; Rabusa C; Proudman S; Roddy J; Zochling J; Hill C; Sturgess A; Tymms K; Youssef P; Sahhar J
Clin Exp Rheumatol; 2016; 34 Suppl 100(5):170-176. PubMed ID: 27049330
[TBL] [Abstract][Full Text] [Related]
19. Maintenance therapies for proliferative lupus nephritis: mycophenolate mofetil, azathioprine and intravenous cyclophosphamide.
Contreras G; Tozman E; Nahar N; Metz D
Lupus; 2005; 14 Suppl 1():s33-8. PubMed ID: 15803929
[TBL] [Abstract][Full Text] [Related]
20. Membranous lupus nephritis in a renal allograft: response to mycophenolate mofetil therapy.
Denton MD; Galvanek EG; Singh A; Sayegh MH
Am J Transplant; 2001 Sep; 1(3):288-92. PubMed ID: 12102264
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
